

You're Invited

The WISRD Spring Community Poster Session and Lecture Series

Dr. Dean Ho

UCLA

Augmented AI and Nanomedicine: The Future of Healthcare

WISRD Poster Session on Current Research

Ahmanson AR/VR Research Lab
Engineering Research
Earth/Space Lab
Life Sciences Lab
Systems Integration

April 30th

Poster Session – 6:30 P.M.

Lecture – 7:30 P.M.

Wildwood School
11811 W. Olympic Blvd
Los Angeles CA. 90064



DEAN HO, Ph.D.

Augmented AI and Nanomedicine: The Future of Healthcare

Novel technologies including artificial intelligence (AI) and nanomedicine are changing the way that medicine is practiced. Key challenges in healthcare, ranging from individualizing patient treatment to improving the targeted delivery of therapies are being overcome with these emerging platforms. This talk will highlight our team's advances in bringing powerful AI and nanomedicine approaches into the clinic, and how our technologies are markedly enhancing treatment outcomes for patients.

Bio

Dr. Dean Ho is currently a Professor in the Division of Oral Biology and Medicine at the UCLA School of Dentistry, Co-Director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, Professor of Bioengineering (courtesy), and member of the Jonsson Comprehensive Cancer Center and California NanoSystems Institute at UCLA.

Dr. Ho and collaborators are developing novel personalized medicine technologies (Augmented AI) based on the field of Phenotypic Personalized Medicine (PPM) to optimize clinical efficacy and safety for several combination therapy indications. He co-led the first in-human trial to personalize and optimize combination therapy for the entire duration of care, an unprecedented achievement. As the Director of Project NDX, he pioneered the development of nanodiamond platforms for the marked enhancement of efficacy and safety of drug delivery and imaging. Recently, Dr. Ho initiated a landmark first in-human clinical trial to validate a nanodiamond-biomaterial device to enhance root canal therapy.

Dr. Ho has appeared on the National Geographic Channel Program “Known Universe” to discuss his discoveries in nanodiamond drug delivery and imaging. He also recently served as a panelist at the XPRIZE Future of Medicine and InnovFest Unbound events, and his achievements have been featured on CNN, The Economist, Forbes, Washington Post, NPR and other international news outlets. Dr. Ho has served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a 26,000-member global drug development organization comprised of senior executives from the pharmaceutical and medical device sectors, as well as academic visionaries. In this capacity, he led a team of pharmaceutical and medical device executives that partnered with the SLAS professional team to expand SLAS into Asia and Europe, pursuing mergers and acquisitions opportunities and establishing offices in Shanghai and Brussels. As SLAS President, Dr. Ho established the Quantitative Bioscience Graduate Fellowship Program with a \$1 million dollar earmark.

Dr. Ho was recently named a Fulbright Scholar. He is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and Society for Laboratory Automation and Screening. He is also a recipient of the NSF CAREER Award, Wallace H. Coulter Foundation Translational Research Award, V Foundation for Cancer Research V Scholar Award, IADR William J. Gies Award, IADR Young Investigator Award, and Distinguished Young Alumnus award of the UCLA School of Engineering. He is a co-founder of multiple companies that are commercializing his drug development technologies, and currently advises venture capital/global equities funds, and several startups. He also served as an instructor for the Science for Managers program at the Kellogg School of Management at Northwestern University.